| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Masafumi Fukagawa | Q56997226 |
| P2093 | author name string | Motoko Tanaka | |
| Shohei Nakanishi | |||
| Yasuhiro Hamada | |||
| P2860 | cites work | Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia | Q24623628 |
| Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) | Q28236767 | ||
| Regulation of fibroblast growth factor-23 signaling by klotho | Q28587100 | ||
| Osteoclast differentiation and activation | Q29547556 | ||
| Cell biology of parathyroid gland hyperplasia in chronic renal failure. | Q33924038 | ||
| Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. | Q34384786 | ||
| Management of patients with advanced secondary hyperparathyroidism: the Japanese approach. | Q34799722 | ||
| Review on uremic toxins: classification, concentration, and interindividual variability | Q35098883 | ||
| Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency | Q35208799 | ||
| Calcium abnormalities of dialysis patients. | Q36406652 | ||
| PTH(1-84)/PTH(7-84): a balance of power | Q36443039 | ||
| Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. | Q36523938 | ||
| Can hyperparathyroid bone disease be arrested or reversed? | Q36910365 | ||
| Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro | Q37355688 | ||
| Renal bone disease 1990: an unmet challenge for the nephrologist | Q37953234 | ||
| Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. | Q40305016 | ||
| Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. | Q40447584 | ||
| Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. | Q40447591 | ||
| Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. | Q40684224 | ||
| Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients | Q40684299 | ||
| Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity | Q40721603 | ||
| Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism | Q41408951 | ||
| Overproduction of an amino-terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery | Q42479544 | ||
| Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia | Q43440194 | ||
| Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients | Q44456551 | ||
| Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism: multicentre trial | Q44456555 | ||
| Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia | Q44545038 | ||
| Clinical experience with percutaneous ethanol injection therapy in hemodialysis patients with renal hyperparathyroidism | Q44603647 | ||
| Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism | Q44647160 | ||
| Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model | Q44745217 | ||
| Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. | Q44985964 | ||
| Infarction of mediastinal parathyroid gland causing spontaneous remission of secondary hyperparathyroidism | Q45071583 | ||
| Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats | Q45170032 | ||
| Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. | Q45968100 | ||
| K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease | Q46286369 | ||
| Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. | Q46572840 | ||
| High serum estradiol concentrations in postmenopausal women with end-stage renal disease. | Q46823879 | ||
| Is the volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism? | Q50735158 | ||
| A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. | Q53667768 | ||
| On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using “proportional reduction” of dietary phosphorus intake | Q53861205 | ||
| Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. | Q54194022 | ||
| Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. | Q54593796 | ||
| Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. | Q54651379 | ||
| Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay | Q69223392 | ||
| The spectrum of bone disease in end-stage renal failure--an evolving disorder | Q70580279 | ||
| Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism | Q71092101 | ||
| Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism | Q71184058 | ||
| Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients | Q72432019 | ||
| Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy | Q72559006 | ||
| Evidence for abnormal calcium homeostasis in patients with adynamic bone disease | Q72898122 | ||
| A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure | Q73194367 | ||
| Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone | Q73235636 | ||
| Evaluation of blood supply to the parathyroid glands in secondary hyperparathyroidism compared with histopathology | Q73444940 | ||
| Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism | Q73487070 | ||
| Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis | Q73804043 | ||
| Risk factors for vertebral fractures in renal osteodystrophy | Q74451547 | ||
| Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure | Q77726105 | ||
| Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients | Q77823315 | ||
| Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism | Q79317303 | ||
| Pathogenic mechanisms for parathyroid hyperplasia | Q79817446 | ||
| Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidism | Q79832181 | ||
| Does cinacalcet safely and effectively maintain long-term PTH control in secondary hyperparathyroidism? | Q80166808 | ||
| Improvement in hypercalcemia with cinacalcet after kidney transplantation | Q80796937 | ||
| Overproduction and secretion of a novel amino-terminal form of parathyroid hormone from a severe type of parathyroid hyperplasia in uremia | Q80796984 | ||
| Normalization of reversed bio-intact-PTH(1-84)/intact-PTH ratio after parathyroidectomy in a patient with severe secondary hyperparathyroidism | Q80943220 | ||
| An overview of regular dialysis treatment in Japan as of 31 December 2003 | Q81626798 | ||
| Autoinfarction of the parathyroid gland diagnosed by power Doppler ultrasonography in a patient with secondary hyperparathyroidism | Q81645130 | ||
| With or without the kidney: the role of FGF23 in CKD | Q81666635 | ||
| Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism | Q81853118 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 434-438 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Journal of Bone and Mineral Metabolism | Q15767236 |
| P1476 | title | The kidney and bone metabolism: Nephrologists' point of view | |
| P478 | volume | 24 |
| Q48063902 | An introduction to CKD-MBD research: restart for the future |
| Q43530796 | Association between low renal function and tooth loss over 5 years. |
| Q40759587 | Bidirectional relationship between renal function and periodontal disease in older Japanese women |
| Q37081787 | Biomarker candidates for cardiovascular disease and bone metabolism disorders in chronic kidney disease: a systems biology perspective |
| Q37244863 | Can features of phosphate toxicity appear in normophosphatemia? |
| Q38635767 | Chronic Kidney Disease-Mineral and Bone Disorder in Asia |
| Q43427754 | Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder |
| Q47816030 | Fibroblast growth factor 23 and calcium phosphate homeostasis after pediatric renal transplantation |
| Q36992835 | Genetic induction of phosphate toxicity significantly reduces the survival of hypercholesterolemic obese mice |
| Q38092144 | Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy. |
| Q35959137 | Idiopathic Recurrent Calcium Urolithiasis (IRCU): pathophysiology evaluated in light of oxidative metabolism, without and with variation of several biomarkers in fasting urine and plasma--a comparison of stone-free and -bearing male patients, emphas |
| Q42177717 | Impact of Different Levels of iPTH on All-Cause Mortality in Dialysis Patients with Secondary Hyperparathyroidism after Parathyroidectomy. |
| Q28535055 | Inadequate awareness among chronic kidney disease patients regarding food and drinks containing artificially added phosphate |
| Q50917530 | Not only for the risk of bone fracture. |
| Q35059741 | Osteo-renal regulation of systemic phosphate metabolism |
| Q35059905 | Phosphate toxicity: new insights into an old problem |
| Q46367732 | Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis |
| Q37108009 | Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease |
| Q40318220 | The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism |
Search more.